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GuidelineAbstract Background: Brain metastases (BM) are frequent in non-small cell lung cancer
(NSCLC) patients, but there is a lack of evidence-based management of this patient group.
We aimed to capture a snapshot of routine BM management in Europe to identify relevant
research questions for future clinical trials.
Methods: An EORTC Lung Cancer Group (LCG) online survey containing questions on
NSCLC BM screening and treatment was distributed between 16/02/17 and 15/06/17 to world-
wide EORTC LCG members, and through several European scientific societies in the thoracic
oncology field.
Results: A total of 462 European physician responses (394 institutions) were analysed (radia-
tion oncologist: 53% [n Z 247], pulmonologist: 26% [n Z 119], medical oncologist: 18%
[n Z 84]; 84% with >5 years’ experience in NSCLC). Italy (18%, n Z 85), Netherlands
(15%, n Z 68), UK (14%, n Z 66), and France (12%, n Z 55) contributed most. 393 physi-
cians (85%) screened neurologically asymptomatic patients for BM at diagnosis (52% using
magnetic resonance imaging). Most often screened patients were those with a driver mutation
(MUTþ; 51%, n Z 234), stage III (63%, n Z 289), and IV (43%, n Z 199). 158 physicians
(34%) used a prognostic classification to guide initial treatment decisions, and in 50%, lowest
prognostic-score threshold to receive treatment differed between MUTþ and non-driver mu-
tation (MUT) patients. MUTþ patients with >4 BM were more likely to receive stereotactic
radiosurgery (SRS) compared with MUT (27% versus. 21%; p < 0.01). Most physicians
(90%) had access to SRS. After single BM surgery, 50% systematically prescribed SRS or
WBRT, and 45% only in case of incomplete resection. The preferred treatment in neurologi-
cally asymptomatic treatment-naive patients diagnosed with >5 BM was systemic treatment
(79%). Of all, 45%/49% physicians stated that all tyrosine kinase inhibitors and immune check-
point blockers were discontinued (timing varied) during SRS/WBRT, respectively. Drugs most
often continued during SRS/WBRT were erlotinib (44%/40%), gefitinib (39%/34%), afatinib
(29%/25%), crizotinib (33%/26%) and anti-PD-(L)-1 (28%/22%).
Conclusion: BM management is highly variable in Europe: screening is not uniform, prog-
nostic classifications are not often used and MUTþ NSCLC patients generally receive more
intensive local treatment. Prospective assessment of BM management in MUTþ NSCLC pa-
tients is required.
ª 2018 Elsevier Ltd. All rights reserved.1. Introduction
Brain metastases (BM) are associated with a detrimental
outcome and a negative impact on quality of life (QoL).
Approximately 40% of non-small cell lung cancer
(NSCLC) patients will present with or develop BMduring
their disease. This rate can increase to up to 80% in
molecularly selected groups, such as anaplastic lymphoma
kinase (ALK ) positiveNSCLCpatients [1]. This incidence
of BM is anticipated to increase over time due to advances
in diagnosis (mainly brain magnetic resonance imaging
[MRI]) and due to the extended overall survival reported
in patientswithBMas a result of better systemic treatment
options [2]. Radiation therapy (SRS: stereotactic radio-
surgery) and surgery are standard local treatments for the
management of patients with a limited number of BM [3].Whole brain radiotherapy (WBRT) alone was until
recently the preferred option for patients who are not
candidates for surgery or SRS, but its role has been chal-
lengedby recent randomised phase III trials [4e6].Despite
the limited penetration of drugs through the bloodebrain
barrier (BBB), chemotherapy or tyrosine kinase inhibitors
(TKI) can beused upfront in neurologically asymptomatic
NSCLC patients without (MUT) andwith an oncogenic
driver mutation (MUTþ), respectively [7e11]. Further-
more, newer TKI generations with superior central ner-
vous system (CNS) penetration rates are already available
(e.g. osimertinib for epidermal growth factor receptor
[EGFR] mutated patients, and ceritinib or alectinib for
ALK) or in late-stage development (e.g. brigatinib and
lorlatinib [ALK]) [1,12e14]. Immune checkpoint blockers
(ICBs) have recently become available for NSCLC
A. Levy et al. / European Journal of Cancer 93 (2018) 37e46 39treatment (e.g. pembrolizumab, nivolumab) and are also
under investigation in NSCLC patients with BM [15].
BM management becomes increasingly important, but
there are still numerous variations in their management.
Local practices and used guidelines may differ
[3,7,16e18] (Table S1). There is heterogeneity in the ac-
cess to modern management across countries, including
equipment (brain MRI, SRS facilities), and access to
newer systemic treatments [19e21]. Indications for SRS
(maximum and number of eligible BM, but also used
prognostic indicators) are likewise not well defined [22].
The paucity of evidence and the lack of large ongoing
trials, regarding the routine management of this patient
group in Europe led to the development of this European
survey. We aimed to capture a snapshot of BM screening
and management in NSCLC patients and to identify
relevant research questions for future clinical trials.
2. Methods
2.1. Study design and population
An online (Google form) survey developed by the
Young Investigators (YI) European Organisation for
Research and Treatment of Cancer (EORTC) Lung
Cancer Group (LCG) was distributed on 16/02/17 to all
EORTC LCG and radiation oncology group (ROG)
worldwide members. National cancer societies in
Europe (medical oncology, pulmonology, neurology,
radiation oncology) were also contacted with the ques-
tion to forward the survey to their members. Responses
were collected until 15/06/2017.
2.2. Description of the survey
The survey was strictly confidential and anonymous.
The questionnaire was divided into six sections: physi-
cian demographic data, screening, initial treatment de-
cision, surgery, radiotherapy, and systemic treatments
questions. The questionnaire consisted of 27 questions,
of which 6 were ‘tick boxes’ type questions. The survey
was reviewed by all EORTC LCG board members
(N Z 12), and all EORTC LCG YI (N Z 32). The
questionnaire was designed to be completed in approx-
imately 10 min. A copy of the full survey is available in
the Supporting Information.
2.3. Statistical analysis
As the aim of the survey was to have a snapshot of BM
management in Europe, and therefore only answers from
European physicians were selected for the analysis. The
Chi-squared or Fisher exact tests were used for dichot-
omous variables comparison (type of speciality: radiation
oncologists versus medical oncologists/pulmonologistsand type of institution: cancer centre/university hospitals
versus private/general hospitals). Paired comparisons of
similar questions were performed using the Bhapkar test.
A two-sided P-value <0.05 was considered significant.
All analyses were performed using software SPSS version
19.0 (SPSS Inc., Chicago, Illinois).3. Results
3.1. Physician demographical data
A total of 485 worldwide responses were collected, and
462 European responses from 394 institutions were
analysed (exclusion of 23 responses [5%] from outside
Europe). Italy (n Z 85; 18.3%), the Netherlands
(n Z 68; 14.7%), UK (n Z 66; 14.3%), and France
(n Z 55; 11.9%) contributed most (Fig. 1; Table S2).
Physicians specialities were: radiation oncologist: 53.4%
(n Z 247), pulmonologist: 25.6% (n Z 119), medical
oncologist: 18.2% (n Z 84), and others: 3% (n Z 12).
Most (84.4%; n Z 390) physicians had >5 years of
experience in NSCLC treatments, and 94% (n Z 436)
had completed their postgraduate education. Hospital
types were: university hospital (43%; n Z 198), general
public hospital (29%; n Z 132), cancer centre (20%;
nZ 92), private centre (7%; nZ 33) and others (nZ 7).
3.2. Initial treatment decision
Of all, 85% physicians (n Z 393) declared to screen
neurologically asymptomatic patients for BM at diag-
nosis. Of these, 52.2% used MRI; private/general in-
stitutions used more MRI than university/cancer
centres: 59% versus 48%, p Z 0.03 (there was no dif-
ference in MRI use according to the doctors’ speciality
[p Z 0.2]). Hundred and twenty-five (27%) physicians
stated that they screened all NSCLC patients. Most
physicians screened patients with stage III (63%), and
MUTþ (51%). 4343% screened stage IV, and 39
screened stage IeII before treatment (Fig. 2; Table S3).
A prognostic classification to guide initial treatment
decisions was used by 34.2% (n Z 158/462; Fig. S1).
Prognostic classification to guide initial treatment de-
cisions were more often used by radiation oncologists
than medical oncologists/pulmonologists (46.6% versus
19.6%, p < 0.001; there was no difference according to
the type of institution [p Z 0.3]). Recursive partitioning
analysis (RPA) was the most often used prognostic
classification (117/158; 74%). Graded prognostic
assessment (GPA), and ds (diagnosis-specific)-GPA
classifications were used by 68/158 (43%) and 30/158
(19%) of the physicians, respectively (total is >100%
given that some physicians used more than one score;
Fig. 2; Table S3). The median lowest prognostic-score
thresholds to receive treatment were 2 (range: 1e3),
Fig. 1. Participating countries. Indicated numbers only if > 5 responses/country. Abbreviations: Herz.: Herzegovina; Lux: Luxembourg.
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and ds-GPA, respectively. In 50%, lowest prognostic-
score threshold to receive treatment differed between
MUTþ and non-driver (MUT) patients (no further
question on the actual difference in score). Ten physi-
cians did not use a prognostic score but used perfor-
mance status (Karnofsky score or World Health
Organisation [WHO]) only.
3.3. Local treatments
SRS was accessible for the majority (90%; n Z 415,
including 97 physicians that did not have direct access to
SRS but could easily refer patients; Table 1). No data
were provided regarding SRS delivery delay in "referred
patients". There was no difference in SRS accessibility
according to the type of institution (p Z 0.05). BM
surgery was most often considered when patients had a
single BM (when symptomatic: 84% [n Z 390/462];when asymptomatic: 61% [n Z 284/462]), when
decompression was necessary (77%; n Z 357/462) and
for histological diagnosis when no other biopsy for
diagnostic purposes were possible (71%; n Z 329/462;
Table 1). Patients with >1 BM were less frequently
considered for surgery (when symptomatic: 29%
[n Z 135/462]; when asymptomatic: 14% [n Z 65/462]).
After single BM surgery, 50.4% routinely prescribed
SRS (n Z 136/462; 29.4%) or WBRT (n Z 97/462;
21%), and 45% only in case of incomplete resection
(SRS: 32% [n Z 148]; WBRT: 13% [n Z 60]). Twenty-
one (4.5%) never applied post-operative radiotherapy.
There was no difference in postoperative radiotherapy
strategy according to the type of institution (p Z 0.6) or
the speciality (p Z 0.08).
Physicians most often considered 3 BM as maximum
‘cut-off number’ for SRS eligibility (MUT-: n Z 220
[48%]; MUTþ: 197 [43%]). Patients with >4 BM were
more likely to receive SRS if MUTþ compared with
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Fig. 2. Initial treatment decision. *Results among 158/462 physicians using a prognostic classification to guide initial treatment decision;
some physicians used >1 classification therefore % is >100%. Abbreviations: MUTþ, oncogenic driver mutation; BM, brain metastases;
RPA, recursive partitioning analysis; GPA, graded prognostic assessment; ds-GPA, diagnosis-specific GPA.
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p < 0.01; Tables 2 and 3). The decision to give SRS was
based on tumour volume (and not a specific threshold
number of BM) for 11% (n Z 53 MUT) and 13%
(n Z 59 MUTþ). There was no difference in the
routinely used BM “cut-off number” for SRS eligibility
according to the speciality (radiation oncologists versus
medical oncologists/pulmonologists; MUT: p Z 0.9;
MUTþ: p Z 0.9) or the type of institution (cancer
centre/university hospital versus private/general hospi-
tal; MUT: p Z 0.8; MUTþ: p Z 0.9). The maximum
BM size to consider a patient eligible for SRS was 3 cm
for 61% (n Z 284) of physicians (2 cm: 11%; 4 cm: 20%;
5 cm: 8%). Radiation oncologists considered larger BM
size for SRS eligibility than medical oncologists/pul-
monologists (4 cm: 32% versus 22%, respectively,
p Z 0.03).
The regimens used to deliver WBRT were 30 Gy in 10
fractions (n Z 234; 51%), 20 Gy in 5 fractions (n Z 142;
31%), both (n Z 55; 12%) or others (n Z 31; 7%). One
hundred eight (23%) physicians offered neuroprotective
WBRT outside of a clinical trial (hippocampal sparing:
n Z 102; neuroprotective agent [memantine or done-
pezil]: n Z 6).
Three hundred fifty-four (77%) physicians were aware
of the QUARTZ trial publication [4]. QUARTZ trial
results influenced the decision to give WBRT in 39.1% of
physicians (n Z 181) who now use less WBRT in poor
prognosis patients. Among those physicians, groups of
patients not considered anymore for WBRT were those
with poor PS (175/181; 97%), uncontrolled extracranial
disease (114/181; 63%), and those suitable for systemic
treatments (53/181; 29%). One hundred seventeen of 281
physicians who did not modify their WBRT prescription
based on the QUARTZ trial results also did not use a
prognostic score to select treatment options.In a growing lesion after SRS that could be either
progressive disease (PD) or radionecrosis, 434 physi-
cians (94%) had access to dynamic MRI and 162 (35%)
to brain biopsy as a diagnostic tool. Forty-nine (11%)
used specifically bevacizumab as a therapeutic tool.
3.4. Systemic treatments questions
The preferred treatment in neurologically asymptomatic
treatment-naive patients diagnosed with >5 BM was
(Table 3) systemic treatment (n Z 364; 78.8%) if MUT-
and molecularly targeted therapies (e.g. TKI; n Z 391
[85%]) if MUTþ. If BM progressed in a MUTþ patient,
the preferred treatment options were second-line TKI
(324; 70%) in case of extracranial progression, and local
treatment with TKI continuation (355; 76.8%) in those
cases with no extracranial progression. There was no
difference according to the type of institution in the
previously described systemic treatment strategy. Med-
ical oncologists/pulmonologists stated in a higher pro-
portion that second-line TKI was their preferred
treatment in neurologically asymptomatic treatment-
naive patients diagnosed with >5 BM (93% versus
80% for radiation oncologists; p < 0.001). If BM pro-
gressed in a MUTþ patient with extracranial progres-
sion, radiation oncologists favoured local treatment
with TKI continuation (21%) more than medical on-
cologists/pulmonologists (10%; p < 0.001).
44.6% (n Z 206)/49.4% (n Z 228) physicians stated
that all TKI and ICBs were discontinued during SRS/
WBRT, respectively. Radiation oncologists dis-
continued TKI-ICB during brain irradiation more often
than medical oncologists/pulmonologists (SRS: 51%
versus 37%, respectively, p Z 0.004; WBRT: 55%
versus 42%, respectively, p Z 0.008; no difference ac-
cording to the type of institution). Drugs most
Table 1
Local treatments.
n (%)
Surgery indications
Single BM
Symptomatic 390 (84)
Asymptomatic 284 (61)
Multiple BM
Symptomatic 135 (29)
Asymptomatic 65 (14)
Decompression 357 (77)
Possible access to SRS
Yes 318 (69)
No but I can easily refer patient 97 (21)
No 47 (10)
Adjuvant radiotherapy indication after a single BM resection
Always SRS 136 (29.4)
Always WBRT 97 (21)
Incomplete resection
SRS 148 (32)
WBRT 60 (13)
Never 21 (4.5)
Maximum BM number for SRS eligibility
MUT MUT+
1 13 (3) 12 (3)
Up to 3 220 (48) 197 (43)
Up to 4 78 (17) 71 (15)
Up to 5 73 (16) 87 (19)
Up to 10 18 (4) 28 (6)
Decision based on total tumour volume only 53 (11) 59 (13)
No maximum 7 (2) 8 (2)
Maximum BM size for SRS eligibility
2 cm 50 (11)
3 cm 284 (61)
4 cm 91 (20)
5 cm 37 (8)
Neuroprotective WBRT outside of a clinical trial
No 354 (77)
Hippocampal sparing 102 (22)
Neuroprotective agent 6 (1)
Less WBRT prescription in poor prognosis patients based on QUARTZ
trial results
Yes 181 (39)
No 173 (38)
Not aware of the publication 108 (23)
Strategy in a growing lesion after SRS that could be either PD or
radionecrosis
Dynamic MRI as a diagnostic tool 434 (94)
Brain biopsy as a diagnostic tool 162 (35)
Bevacizumab as a therapeutic tool 49 (11)
Abbreviations: BM: brain metastases; RPA: Recursive partitioning
analysis; GPA: Graded prognostic assessment; ds-GPA: diagnosis-
specific GPA: SRS: radiosurgery; WBRT: Whole brain radiotherapy.
Table 2
Systemic treatments questions.
n (%)
Preferred treatment in neurologically asymptomatic treatment-naive
patients diagnosed with >5 BM
MUT MUT+
Bevacizumab
containing regimen
34 (7) 14 (3)
Driver mutation
specific treatment (e.g. TKI)
6 (1) 391 (85)
Other 43 (9) 27 (6)
PD-(L)1 inhibitors 15 (3) 5 (1)
Platinum-based doublet 364 (79) 25 (5)
Preferred treatment if BM progressed in a MUT+ patient
with
extracranial
PD
without
extracranial
PD
Local treatment
and continue TKI
88 (19) 355 (77)
Second line TKI 324 (70) 73 (16)
Other 50 (11) 34 (7)
Drugs continued during brain RT
SRS WBRT
None 206 (44.6) 228 (49.4)
Erlotinib 203 (44) 185 (40)
Gefinitib 180 (39) 157 (34)
Crizotinib 152 (33) 120 (26)
Anti-PD-(L)-1 129 (28) 102 (22)
Duration of discontinuation during brain RT
SRS WBRT
1 day before until
1 day after RT
49 (11) 30 (6)
3 days before, until
3 days after RT
117 (25) 128 (28)
3 T1/2, until
3 T1/2 after RT
48 (10) 52 (11)
5 T1/2 before, until
5 T1/2 after RT
31 (7) 36 (8)
During cranial
radiotherapy
61 (13) 58 (13)
Other 44 (10) 43 (9)
NA 112 (24) 115 (25)
Reasons for continuing the targeted agent during cranial radiotherapy
Absence of perceived safety issues 217 (47)
Risk of systemic flare 176 (38)
Possible radiosensitising effects 134 (29)
Abbreviations: BM: brain metastases; RT: radiotherapy; SRS: radio-
surgery; WBRT: Whole brain radiotherapy; T1/2: halftime of the drug;
PD: progressive disease; MUT: oncogenic driver mutation; TKI:
tyrosine-kinase inhibitor; PD-L1: programmed-death ligand 1; NA: no
answer.
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were erlotinib (44e40%), gefitinib (39e34%), afatinib
(29e25%), crizotinib (33e26%) and anti-PD-(L)-1 (28-
22%). Timing varied, but the most frequent duration of
discontinuation was 3 days before and 3 days after RT
(25e28%). The reasons mentioned by physicians for
continuing the targeted therapy during cranial radio-
therapy were the absence of perceived safety issues
(47%) and/or risk of systemic flare (38%), or thepossible radiosensitising effects (29%). A proportion of
44.8% (n Z 207) physicians stated that they used
WBRT to increase the systemic treatment efficacy
through BBB disruption.4. Discussion
To the best of our knowledge, this is the first BM Eu-
ropean survey collecting data on screening, treatment
decisions, radiation and systemic therapy practice spe-
cifically in NSCLC patients, including data on patients
with driver mutations. Other surveys (range of number
Table 3
Management variations according to the presence of an oncogenic
driver mutation (eg. EGFR, ALK).
Overall
n (%)
MUT
n (%)
MUT+
n (%)
p
Screening at any stage 125 (27) 234 (51) e
Different p-score
threshold in MUT+
e e 79 (50)a e
Maximum n of BM
for SRS eligibility
4 e 311 (67) 280 (61) <0.01b
>4 e 98 (21) 123 (27)
Decision based on
total tumour volume
53 (11) 59 (13)
No maximum 7 (2) 8 (2)
Abbreviations: MUT: oncogenic driver mutation; p: prognostic; BM:
brain metastases; SRS: radiosurgery.
a Total Z 158 physicians using a prognostic classification to guide
initial treatment decision.
b Bhapkar test.
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of patients with BM were not specific to lung cancer,
and predominantly included radiation oncologists from
the USA and Australia (Table S4) [23e29].
Our results highlight the current heterogeneous
practice patterns and decision-making processes. BM
screening practice varied widely: 63% screened all stage
III, 43% screened all stage IV patients, and only half
used MRI for screening purposes. According to ESMO
(European Society for Medical Oncology) guidelines,
brain imaging (preferably contrast-enhanced MRI): i)
might be useful in early and locally advanced patients
considered for curative therapy [30], ii) should be per-
formed in all patients planned for curative stage III
NSCLC treatment [30], and iii) is most relevant in stage
IV patients with neurological symptoms or signs,
although screening all stage IV patients should be
considered [7]. Possibly, the low use of MRI in our
survey can be explained by limited access to MRI in a
timely fashion, as described in another survey [29]. Ac-
cording to the Organisation for Economic Co-operation
and Development, the median number of MRI equip-
ment per 1,000,000 inhabitants is three time higher in
the USA as compared with the European union (36.7
versus 12.3 [range, 3.6e33.6], respectively) [21]. Prog-
nostic scores were used by only 34% of physicians (and
mainly by radiation oncologists), despite being consid-
ered key information in decision-making in this group of
patients [31e33]. The ESMO guideline on metastatic
NSCLC recommends that the RPA classification is
used, and that radiotherapy in poor prognosis patients
(RPA class III) should not be offered [7].
Regarding local treatments, most physicians consid-
ered 3 BM as maximum for SRS eligibility (MUT:
n Z 220 [48%]; MUTþ: 197 [43%]) and/or 3 cm as a
maximum BM size (61%). It should be noted that SRS
using a unique fraction versus a hypo-fractionatedprocedure was not individualised in the survey. Few
respondents (10%) now use total volume rather than
number of BM to make SRS decision. Yamamoto et al.
[33] have recently showed that SRS without WBRT was
feasible as the initial treatment for patients with five to
ten BMs, if the cumulative volume of all BMs
is  15 mL. Sandler et al. have performed a survey of
711 practicing radiation oncologists, and it was found
that the optimal BM ‘cut-off number’ for SRS was
significantly higher for high-volume CNS centres (10
patients/month) than for either low-volume CNS centres
(5e9 patients/month) or high-volume, non-CNS spe-
cialists (number of BM: 8.1 versus 5.6 and 5.1, respec-
tively; p < 0.001) [26]. In our study, there was no
difference in the optimal ‘cut-off number’ according to
the institution type. Results on the ongoing randomised
trials comparing SRS and WBRT for patients with four
to ten BMs (NCT02353000, primary endpoint QoL 3
months after radiotherapy) will hopefully better define
the role of SRS in this setting.
The preferred treatment in neurologically asymp-
tomatic treatment-naive patients diagnosed with >5 BM
was systemic chemotherapy (78.8%) in MUT- and TKI
(85%) in MUTþ patients. In accordance with ESMO
guidelines [7], physicians surveyed stated that systemic
treatments should be initiated in non-symptomatic pa-
tients with multiple BM. Intracranial response rates
slightly below extracranial response rates have been
observed with first-line chemotherapy or first-line TKI
in MUTþ patients, with the possibility to delay or
withhold WBRT [8e11,34]. However, a recent retro-
spective report showed that EGFR-TKI, and deferral of
radiotherapy, was associated with inferior outcomes in
patients with EGFR-mutant NSCLC [35]. To the best of
our knowledge, there are no completed trials comparing
upfront cranial radiotherapy followed by a TKI to
upfront TKI in MUTþ patients with BM. Such trial
investigating gefitinib in EGFR-mutant NSCLC
(NCT01363557) was prematurely closed due to poor
accrual. However, based on the heterogeneous man-
agement of BM in MUTþ patients, trials evaluating the
sequencing of cranial radiotherapy and targeted thera-
pies mentioned above are warranted. Another strategy is
the evaluation upfront newer generation TKIs in pa-
tients with BM and driver mutations. Recently, it was
shown that first-line alectinib (ALKþ patients) and
osimertinib (EGFR-mutated patients) provided superior
intracranial control compared with standard of care
[1,36]. This survey shows that, in the routine setting,
MUTþ NSCLC patients generally received more
aggressive local treatment. This group was more
frequently screened for BM, in all stages of disease (234;
51%), and in 50%, the lowest prognostic-score threshold
to receive treatment differed between driver MUTþ and
MUT patients. MUTþ patients with >4 BM were also
more likely to receive SRS than MUT- NSCLC patients
(p < 0.01; Table 3).
A. Levy et al. / European Journal of Cancer 93 (2018) 37e4644More than half of physicians did not discontinue TKI
and ICB during SRS (55.4%)/WBRT (50.6%). Drugs
most often continued (SRS-WBRT) were TKI (29%e
44% e 25e40%) and the main reasons for continuing
the targeted agent during cranial radiotherapy were the
absence of perceived safety issues (47%). A phase II
study demonstrated that erlotinib is well tolerated in
combination with WBRT [37]. However those results
may not be extrapolated to other TKI and ICB delivered
concurrently with brain irradiation, even if most retro-
spective data are reassuring [38e42]. Ideally, safety and
efficacy should be evaluated within the context of a
clinical trial.
Limitations of this survey include the fact that
number of questions was restricted and therefore cannot
provide a full picture of BM practice, particularly in rare
subgroups of patients (e.g. ROS1), and the absence of a
known response rate, as we do not know the total
number of physicians who received the survey because
of the forwarding by the national societies. We adopted
a pragmatic approach, as it is known that the number of
respondents decreases when the number of questions
and time to survey completion increases. Selection bias
is probable as interested oncologists were more likely to
respond to the survey. This may have impacted on the
results (e.g. high rate of access to SRS of 90%). How-
ever, half of the respondents worked in general and
private hospitals. Furthermore, the respondents repre-
sent a specific population. Indeed most respondents
came from Western Europe (Fig. 1), and the networks
used to send the questionnaire generally targeted a
specific population (physician were the members of sci-
entific society or an organisation that include patients in
trials, with a consequence of relatively few physicians
from private practice [7%]).
5. Conclusion
BM management differed widely within European cen-
tres. Some of the main findings of the survey are that
screening was not uniform and prognostic classifications
were not often used, despite robust evidence in the liter-
ature supporting these strategies. Half of respondents
declared that they routinely deliver adjuvant radio-
therapy, which is demonstrated to decrease the risk of
local recurrence, even if complete resection has been per-
formed [43e45]. Cancer societies’ teachings may focus on
already existing studies and decision-making tools such as
prognostic scores to optimise NSCLC BM management.
MUT þ NSCLC patients generally received more
aggressive local treatment. Specific BM guidelines for
MUT þ NSCLC patients should be written to help phy-
sicians in the management of this patients group. Pro-
spective assessment of BM treatment strategies in
MUTþNSCLC patients is also required. More attention
should as well be paid to BM in MUT patients on
conferences and webinars as the majority of NSCLC BMpatients isMUT. Finally, there is a lack of data on safety
and sequencing of most targeted therapies/ICB combined
with radiotherapy, although trials are ongoing. Efforts in
harmonisation throughout Europe in terms of manage-
ment and screening of BM should be pursued [3,7]
through clinical trials conducted by oncology societies.
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